Filter Results:
(9,755)
Show Results For
- All HBS Web
(9,755)
- People (28)
- News (2,484)
- Research (5,416)
- Events (52)
- Multimedia (189)
- Faculty Publications (3,679)
Show Results For
- All HBS Web
(9,755)
- People (28)
- News (2,484)
- Research (5,416)
- Events (52)
- Multimedia (189)
- Faculty Publications (3,679)
- September 2013 (Revised January 2016)
- Case
The Abraaj Group and the Acibadem Healthcare Investment (A)
By: Paul A. Gompers, Bora Uluduz and Firdevs Abacioglu
This case concerns the proposed buyout of Acibadem, a leading hospital chain in Turkey. Abraaj, a MENA region private equity firm, proposes to make its first investment in Turkey. The case highlights the role of Turkish health care reform in driving the value. The... View Details
Gompers, Paul A., Bora Uluduz, and Firdevs Abacioglu. "The Abraaj Group and the Acibadem Healthcare Investment (A)." Harvard Business School Case 214-021, September 2013. (Revised January 2016.)
- January 2007 (Revised July 2013)
- Case
To JV or Not To JV? That Is the Question (for XTech in China)
By: Daniel J. Isenberg and Paul W. Marshall
XTech, a leading manufacturer of metal parts for the telecommunications industry, is being pushed by its large equipment vendor customers to establish a manufacturing operation in China. CEO Reinhold Hesse is debating several options: establishing a joint venture,... View Details
Keywords: Entrepreneurs; Entrepreneurship; Search; Global Ventures; Succession; Acquisitions; Private Equity; Negotiation; Partners and Partnerships; Expansion; Joint Ventures; Management Succession; Decision Choices and Conditions; Corporate Entrepreneurship; Financing and Loans; Global Strategy; Acquisition; Manufacturing Industry; Telecommunications Industry; China; United States
Isenberg, Daniel J., and Paul W. Marshall. "To JV or Not To JV? That Is the Question (for XTech in China)." Harvard Business School Case 807-118, January 2007. (Revised July 2013.)
- May 1999 (Revised September 2003)
- Case
Advanced Inhalation Research, Inc.
This case presents a look at the early start-up phase and development of Advanced Inhalation Research (AIR), a company engaged in the development of a new drug-delivery technology. Focuses on the risks, the steps taken to manage it, and the manner in which the company... View Details
Keywords: Technological Innovation; Risk Management; Valuation; Financing and Loans; Health Care and Treatment; Acquisition; Business Startups; Medical Devices and Supplies Industry
Roberts, Michael J., and Diana S. Gardner. "Advanced Inhalation Research, Inc." Harvard Business School Case 899-292, May 1999. (Revised September 2003.)
- October 1995
- Case
Johnson-Grace: March 1994
Johnson-Grace is a cash-strapped start-up company negotiating a licensing agreement with America OnLine (AOL), a leading provider of on-line services in the United States. The Johnson-Grace technology would enable AOL to transmit visual images to its customers more... View Details
Bhide, Amar, and Michael Santoro. "Johnson-Grace: March 1994." Harvard Business School Case 396-096, October 1995.
- 22 Oct 2018
- News
New Health Options for Small-Business Employees
- 29 Mar 2023
- Video
The Blavatnik Fellowship: A Lifelong Community of Entrepreneurs
- 11 Jun 2024
- In Practice
The Harvard Business School Faculty Summer Reader 2024
As the vacation season looms, Harvard Business School faculty members share recommendations for a little light reading. Spoiler alert: Lessons in Chemistry tops two of their beach-read lists. For those whose brains can’t—or won’t—turn off, HBS faculty also suggest some... View Details
Keywords: by Avery Forman
- Web
Technology & Operations Management - Faculty & Research
Yanhua Bird, Jodi L. Short and Michael W. Toffel Social movement pressures can lead organizations to concede and improve social performance to avoid disruption costs, but we theorize that such responses evoke concession costs that prompt... View Details
- 13 Jul 2021
- Cold Call Podcast
Strategies for Underdogs: How Alibaba’s Taobao Beat eBay in China
- January 2024
- Teaching Note
Frank Cornelissen: The Great Sulfite Debate (A) & (B)
By: Tiona Zuzul
Teaching Note for HBS Case Nos. 724-391 and 724-398. In 2018, artisanal Italian vineyard Frank Cornelissen was one of the world’s leading natural wine vineyards. Its founder, Frank Cornelissen, faced weather related conditions that forced him to have to decide between... View Details
Keywords: Budgets and Budgeting; Business Earnings; Agribusiness; Plant-Based Agribusiness; Family Business; For-Profit Firms; Small Business; Change Management; Transition; Communication Strategy; Decision Making; Cost vs Benefits; Financial Management; Financial Strategy; Profit; Revenue; Spending; Globalization; Global Strategy; Goods and Commodities; Innovation Strategy; Crisis Management; Goals and Objectives; Growth Management; Success; Strategic Planning; Problems and Challenges; Risk and Uncertainty; Cognition and Thinking; Reputation; Strategy; Adaptation; Expansion; Mission and Purpose; Values and Beliefs; Food and Beverage Industry; Europe; Italy
- July 1994 (Revised December 1994)
- Case
CIGNA Corporation, Inc.: Managing and Institutionalizing Business Reengineering
Provides a longitudinal view of business reengineering at CIGNA Corp., a leading provider of insurance and related financial services throughout the United States and the world. CIGNA has been practicing business reengineering since 1989, completing over 20 projects.... View Details
Stoddard, Donna B., and Sirkka Jarvenpaa. "CIGNA Corporation, Inc.: Managing and Institutionalizing Business Reengineering." Harvard Business School Case 195-097, July 1994. (Revised December 1994.)
- August 2013 (Revised October 2013)
- Case
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
- 04 Apr 2022
- News
Cost of Distancing May Outweigh Benefits for Healthy Adults
- 23 Sep 2021
- News
Eight Ways to Totally Reboot Your Commute
- 06 Oct 2020
- News
Congress made a lousy case for breaking up Big Tech
- 11 Sep 2019
- News
Study says solar cheaper than TVA
- 16 Apr 2020
- News